<DOC>
	<DOCNO>NCT02906670</DOCNO>
	<brief_summary>This first study test Sym013 ( Pan-HER ) human . The primary purpose study see Pan-HER safe effective patient advance epithelial malignancy without available therapeutic option .</brief_summary>
	<brief_title>Sym013 ( Pan-HER ) Patients With Advanced Epithelial Malignancies</brief_title>
	<detailed_description>This open-label , multicenter trial compose 2 part Pan-HER evaluate administer intravenous ( IV ) route weekly schedule patient advance epithelial malignancy without available therapeutic option . Four ( 4 ) dose Pan-HER administered weekly constitute 1 cycle . Part 1 Phase 1a dose-escalation design determine recommend phase 2 dose ( RP2D ) . Part 2 Phase 2a dose-expansion RP2D . Two tumor type evaluate part trial select base upon finding Part 1 , additional preclinical data , additional clinical data available time agent inhibit target . Patients enter , depend upon underlying malignancy , one two correspond expansion cohort : Cohort A Cohort B .</detailed_description>
	<criteria>Main inclusion criterion patient , Part 1 Part 2 : Male female , least 18 year age time inform consent Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 Life expectancy &gt; 3 month assess Screening Documented ( histologically cytologicallyproven ) epithelial malignancy locally advance metastatic , received therapy know confer clinical benefit Additional inclusion criterion applicable Part 2 ONLY : Epithelial malignancy ( type specify CTP amendment ) , measurable accord RECIST v1.1 confirm compute tomography ( CT ) magnetic resonance imaging ( MRI ) within 4 week prior C1/D1 Willingness undergo preand postdosing biopsy ( total 2 biopsy ) primary metastatic tumor site ( ) consider safe biopsy Main exclusion criterion : Any antineoplastic agent ( standard investigational ) within 4 week prior C1/D1 Part 2 ONLY : Radiotherapy target lesion within 4 week prior C1/D1 , unless document progression lesion follow radiotherapy Immunosuppressive systemic hormonal therapy within 2 week prior C1/D1 allow exception Use hematopoietic growth factor within 2 week prior C1/D1 Active second malignancy history another malignancy within last 3 year , allow exception Known central nervous system ( CNS ) leptomeningeal metastasis control prior surgery radiotherapy , symptom suggest CNS involvement treatment require Inadequate recovery acute toxicity associate prior antineoplastic therapy Major surgical procedure within 4 week prior C1/D1 inadequate recovery prior surgical procedure Nonhealing wound part body Active thrombosis , history deep vein thrombosis pulmonary embolism , within 4 week prior C1/D1 , unless adequately treat stable Active uncontrolled bleed know bleed diathesis Significant gastrointestinal abnormality Significant cardiovascular disease condition Abnormal hematologic , renal hepatic function Any follow within 2 week prior C1/D1 : Any serious uncontrolled infection Any infection require parenteral antibiotic Unexplained fever &gt; 38.0 Â°C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Epithelial malignancy</keyword>
</DOC>